US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

by NASDAQ Market News August 3, 2021

NASDAQ Market News
Click here to email author

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA

From the Couch to the Conference Hall—Marketing to the New Hybrid Conference Model

Ads